Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism. [electronic resource]
Producer: 20061124Description: 65-71 p. digitalISSN:- 1537-1891
- Animals
- Cardiolipins -- metabolism
- Cardiovascular System -- drug effects
- Choline-Phosphate Cytidylyltransferase -- antagonists & inhibitors
- Crosses, Genetic
- Diabetes Mellitus, Type 2 -- drug therapy
- Disease Models, Animal
- Fatty Liver -- chemically induced
- Gene Expression Regulation -- drug effects
- Hypoglycemic Agents -- adverse effects
- Liver -- drug effects
- Male
- Mice
- Mice, Inbred NOD
- Mice, Obese
- Mitochondria, Heart -- drug effects
- PPAR gamma -- agonists
- Phosphatidylcholines -- metabolism
- Phosphatidylethanolamine N-Methyltransferase -- antagonists & inhibitors
- Rosiglitazone
- Thiazolidinediones -- adverse effects
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.